Institute of Pathology, Eberhard-Karls-University of Tübingen, Tübingen, Germany.
Mod Pathol. 2011 Aug;24(8):1046-54. doi: 10.1038/modpathol.2011.62. Epub 2011 Apr 15.
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma of the elderly was included as a provisional entity in the 2008 WHO lymphoma classification. Most reports of this disease come from Asia and little is known about it in other regions of the world, including Latin America. Therefore, in this study, 305 diffuse large B-cell lymphomas in patients above 50 years were analyzed, 136 from Mexico and 169 from Germany. EBV was detected by Epstein-Barr early RNA (EBER) in situ hybridization. Only cases with EBER+ in the majority of tumor cells were regarded as EBV+ diffuse large B-cell lymphoma. The prevalence of EBV+ diffuse large B-cell lymphoma in Mexican patients was found to be 7% (9 of 136), whereas only 2% (4 of 169) of the German cases were positive. The median age at diagnosis was 66 years in the Mexican cohort, as opposed to 77 years in the German group. The site of presentation was in both groups predominantly nodal in nine cases (70%) and extranodal in four cases (30%). Of the 13 EBV+ cases, 10 (77%) were classified as polymorphic and 3 (23%) as monomorphic type. The polymorphic cases showed a non-germinal center B-cell immunophenotype (CD10- MUM1+). Twelve cases (92%) were LMP1 positive and two (15%) expressed EBNA2. An interesting finding was the high frequency of EBV type B with the LMP1 30 bp deletion found in the Mexican cases (50%). Eight of the 11 evaluable cases were B-cell monoclonal by polymerase chain reaction. In summary, we found a similar prevalence of EBV+ diffuse large B-cell lymphoma of the elderly in a Mexican population compared with what has been reported in Asian countries, and in contrast to the low frequency in Western populations (1-3%). However, compared with the Asian series, the Mexican patients were younger at diagnosis, presented predominantly with nodal disease and rarely expressed EBNA2 protein.
老年人 EBV 阳性弥漫性大 B 细胞淋巴瘤于 2008 年被 WHO 淋巴瘤分类列为暂定实体。大多数关于这种疾病的报道来自亚洲,而在世界其他地区,包括拉丁美洲,对其了解甚少。因此,在这项研究中,分析了 305 例年龄在 50 岁以上的弥漫性大 B 细胞淋巴瘤患者,其中 136 例来自墨西哥,169 例来自德国。通过 Epstein-Barr 早期 RNA(EBER)原位杂交检测 EBV。只有大多数肿瘤细胞中 EBER+的病例才被视为 EBV+弥漫性大 B 细胞淋巴瘤。在墨西哥患者中 EBV+弥漫性大 B 细胞淋巴瘤的患病率为 7%(136 例中的 9 例),而德国患者中只有 2%(169 例中的 4 例)呈阳性。在墨西哥队列中,中位诊断年龄为 66 岁,而在德国组中为 77 岁。在两个组中,病变部位均主要为淋巴结 9 例(70%)和结外 4 例(30%)。在 13 例 EBV+病例中,10 例(77%)为多形性,3 例(23%)为单形性。多形性病例表现为非生发中心 B 细胞免疫表型(CD10- MUM1+)。12 例(92%)LMP1 阳性,2 例(15%)表达 EBNA2。一个有趣的发现是在墨西哥病例中发现 EBV 型 B 高频存在,LMP1 30bp 缺失(50%)。11 例可评估病例中,8 例通过聚合酶链反应检测到 B 细胞单克隆。总之,我们在墨西哥人群中发现了与亚洲国家报道的老年人 EBV+弥漫性大 B 细胞淋巴瘤相似的患病率,与西方人群(1-3%)的低频率形成对比。然而,与亚洲系列相比,墨西哥患者的诊断年龄较小,主要表现为淋巴结疾病,很少表达 EBNA2 蛋白。